論文

査読有り 国際誌
2022年1月

The SARS-CoV-2 Lambda variant exhibits enhanced infectivity and immune resistance

Cell Reports
  • Izumi Kimura
  • Yusuke Kosugi
  • Jiaqi Wu
  • Jiri Zahradnik
  • Daichi Yamasoba
  • Erika P. Butlertanaka
  • Yuri L. Tanaka
  • Keiya Uriu
  • Yafei Liu
  • Nanami Morizako
  • Kotaro Shirakawa
  • Yasuhiro Kazuma
  • Ryosuke Nomura
  • Yoshihito Horisawa
  • Kenzo Tokunaga
  • Takamasa Ueno
  • Akifumi Takaori-Kondo
  • Gideon Schreiber
  • Hisashi Arase
  • Chihiro Motozono
  • Akatsuki Saito
  • So Nakagawa
  • Kei Sato
  • 全て表示

38
2
開始ページ
110218
終了ページ
110218
記述言語
英語
掲載種別
研究論文(学術雑誌)
DOI
10.1016/j.celrep.2021.110218
出版者・発行元
Elsevier BV

SARS-CoV-2 Lambda, a variant of interest, has spread in some South American countries; however, its virological features and evolutionary traits remain unclear. In this study, we use pseudoviruses and reveal that the spike protein of the Lambda variant is more infectious than that of other variants due to the T76I and L452Q mutations. The RSYLTPGD246-253N mutation, a unique 7-amino acid deletion in the N-terminal domain of the Lambda spike protein, is responsible for evasion from neutralizing antibodies and further augments antibody-mediated enhancement of infection. Although this mutation generates a nascent N-linked glycosylation site, the additional N-linked glycan is dispensable for the virological property conferred by this mutation. Since the Lambda variant has dominantly spread according to the increasing frequency of the isolates harboring the RSYLTPGD246-253N mutation, our data suggest that the RSYLTPGD246-253N mutation is closely associated with the substantial spread of the Lambda variant in South America.

リンク情報
DOI
https://doi.org/10.1016/j.celrep.2021.110218
PubMed
https://www.ncbi.nlm.nih.gov/pubmed/34968415
PubMed Central
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8683271
ID情報
  • DOI : 10.1016/j.celrep.2021.110218
  • ISSN : 2211-1247
  • PubMed ID : 34968415
  • PubMed Central 記事ID : PMC8683271

エクスポート
BibTeX RIS